Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
AbbVie's trading volume on March 13 was $1.26B, ranking 61st among U.S. stocks on that day.
On March 13, 2026, AbbVie (ABBV) had a trading volume of $1.26B, ranking 61st among U.S. stocks that day, a decrease of 26.85% from yesterday, with a trading volume of 5.6739 million.
AbbVie (ABBV) fell 2.52% on March 13, 2026, to $219.68. The stock has declined 4.53% over the past 5 trading days, down 5.34% for the entire month of March, and down 3.86% since the beginning of the year. Over the past 52 weeks, it has increased by 3.84%.
*If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to now (this also applies to cases where the listing duration is less than 1 month or fewer than 5 trading days).
AbbVie was incorporated on April 10, 2012, in Delaware, holding the research-based pharmaceutical business formerly owned by Abbott. The company is a global, research-driven biopharmaceutical company. AbbVie develops and markets advanced therapies to address some of the world’s most complex and serious diseases. Its products focus on treating chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease; low testosterone; HIV; endometriosis; thyroid disorders; Parkinson’s disease; and complications related to chronic kidney disease and cystic fibrosis. AbbVie’s promising pipeline includes over 20 compounds or indications in Phase II or III development, covering key medical fields such as immunology, virology, oncology, nephrology, neurology, and women’s health.